Get Started

PPBT

NASD Purple Biotech Ltd. Sponsored ADR
Nov 8, 2026 · 7:07 AM ET EOD Market Closed

$1.31 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.31, $0.02 below the day’s high of $1.33

YTD change
-80.08%
vs 20-day SMA
+13.27%
vs 200-day SMA
-55.11%

Price ranges

Previous day
$1.15 $1.33
open $1.15 close $1.31
+$0.16 (+13.91%)
Today
$1.15 $1.33
$1.31
Past week
$1.07 $1.34
from $1.09 now $1.31
+$0.22 (+20.18%)
Past month
$0.91 $1.44
from $1.44 now $1.31
-$0.13 (-9.03%)
This year
$0.41 $6.58
from $6.58 now $1.31
-$5.27 (-80.08%)

Price & Performance

-2.81 (-68.24%) / 6M

$0.6679$1.91$3.14$4.38May 8Aug 10Nov 6

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 99.9% away from all-time highs of $1,450.00
  • PPBT is down 80% since the beginning of the year
  • PPBT is down 82% over the past 12 months
  • PPBT is down 9% over the past 1 month
  • 1% of all PPBT investors are betting against PPBT

PPBT reads neutral: price sits above one of the two key moving averages, the 12-month move is +54.8%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.41
Earnings momentum +85.8% Quarterly EPS growth
Quarterly change +85.8%

Valuation

P/E ratio N/A
Enterprise value $-4671340.0
Beta 0.79

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$6.1M
Debt$134.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $1.6M

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $460.42 +0.03%
MRNA Moderna, Inc. $254.19 +5.27%
RVMD Revolution Medicines, Inc. $192.28 +8.24%
ROIV Roivant Sciences Ltd. $38.88 +6.17%
BNTX BioNTech SE Sponsored ADR $87.51 +1.92%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.